drugset
Drugs / 177Lu-FAP-2286
last change Jun 2026 re-read 3 minutes ago

177Lu-FAP-2286

also known as [177Lu]Lu-FAP-2286
Developed for
cancer · cancer of unknown primary site
Investigated by
National Health and Medical Research Council, Australia · Novartis · Novartis Pharmaceuticals · Peter MacCallum Cancer Centre, Australia · SOFIE · University of Melbourne

Trials 2

today NCT07434180 · Ph 2 NCT04939610 · Ph 1/2
202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT04939610 Jul 2021 → Jun 2026 overdue cancer Novartis Pharmaceuticals Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07434180 Jun 2026 → Jun 2030 expected cancer of unknown primary site Peter MacCallum Cancer Centre, Australia Not yet recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as 177Lu-FAP-2286 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07434180 ↗
1

NCT04939610 ↗
Known as [177Lu]Lu-FAP-2286 “Phase I of the LuMIERE study (ClinicalTrials.gov, NCT04939610) investigated the safety of [177Lu]Lu-FAP-2286 (177Lu-FAP-2286) in heavily pretreated patients with advanced solid...” PMID 42223513 ↗ Jun 2026
Route Intravenous “Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses.” NCT04939610 ↗